Ostpo
OstPo formulation is a combination of herbs and isolates, Icariin and Bakuchiol, which directly treat Osteoporosis and support the increase of bone mineral density (BMD).*
Supplement FactsServing Size:1 capsules Servings Per Container: 60 |
||
|---|---|---|
|
Amount Per Serving |
% Daily Value |
|
| Epimedium (leaf) (Yin Yang Huo) | 30mg | † |
| Epimedium (contains icariin extract) (above ground parts) | 100mg | † |
| Japanese teasel (root) (Xu Duan) | 80mg | † |
| Psoralea (fruit) (Bu Gu Zhi) | 30mg | † |
| Psoralea (contains Bakuchiol) (Bu Gu Zhi) | 2mg | † |
| Rehmannia (root) Di Huang | 50mg | † |
| Salvia (root) (Dan Shen) | 60mg | † |
| Anemarrhena (rhizome) (Zhi Mu) | 50mg | † |
| Pyrola Calliantha H Andres (herb) (Lu Xian Cao) | 88mg | † |
Other Ingredients: Vegetable cellulose (hypromellose); Vegetable Stearic Acid; Microcrystalline Cellulose and Vegetable Magnesium Stearate.
Does Not Contain Wheat, gluten, soy, milk, eggs, fish, crustacean shellfish, tree nuts, peanuts
Ostpo
60 x 500 mg Vegetarian Capsules
Product Overview
Ostpo is a formulation of herbs that contain isolates traditionally shown and by modern research to support optimum bone health. Bakuchiol from Psoralea is one such substance. Icariin a flavonol glycoside found in many medicinal plants has also been linked to having a therapeutic role in supporting bone health and supporting optimum bone density. *
Actions
•Supports optimum bone health*
•Supports maintenance of optimum bone density*
Suggested Use:
2-4 capsules daily
Warning:
Do not use if taking Aricept, Reminyl or Exelon, Warfarin, or when pregnant, or nursing.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Patients administered the OSTPO Capsule in clinical trials showed improved bone marrow density and serum oestradiol compared with those administered calcium. However, because of the small sample size of these trials, the conclusions need to be interpreted cautiously, and more well-designed, high-quality random-controlled trials are required.1 Controversy still exists regarding the healing effect and associated mechanism underlying OSTPO capsules in osteoporotic early process fracture healing and ovariectomized patients. In a study involving fifty female 12-week old Sprague-Dawley rats, OSTPO treatment enhanced the bone mineral density, X-ray radiography score and quantity of callus tissues in rats in the ovariectomy and fracture groups. No significant difference was observed in bone morphogenetic protein-2 expression. OSTPO also promoted the early vascular formation of osteoporotic fracture healing in ovariectomized rats.2 *
In a controlled study in 40 female SD rats, OSTPO was found to increase bone density and E2 levels of ovariectomised rats, and is effective in the treatment of osteoporosis.3 *
OSTPO-medicated serum promoted osteoblast mineralization in a mouse osteoblast MC3T3-E1 and an osteoclast induced by a mouse single nucleus macrophage RAW 264 co-culture system. Additionally, it reduced the count of absorption lacuna on bone chips. OSTPO-medicated serum could increase the ratio of OPG/RANKL in a dose dependent manner.4 *
The treatment for osteoporosis is presently targeted on the inhibition of bone-resorption, and OSTPO has been reported to be effective for pro- moting bone formation. In a randomised study involving 24 rats suffering osteoporosis induced by ovariectomy, OSTPO was found to partly prevent bone loss by inhibiting bone resorption and promoting bone formation, thereby reducing the bone turnover level.5 *
Icariin
The effects of icariin treatment combined with exercise therapy on bone parameters and body weight of ovariectomized rats were investigated. Exercise combined with icariin was found to have a synergistic effect in the early prevention of osteoporosis in ovariectomized rats. The effects of icariin and exercise on osteoporosis require further exploration.6 *
Pyrola calloantha and Radix Dipsaci
The effects of herbal medicines, such as Radix Dipsaci (RDD), Pyrola Herb (PHD), and Cynomorium songaricum decoction (CSD), on osteoporotic rats induced by ovariectomy (OVX) have been investigated. Compared to the normal control and non-overiectomized rats, trabecular bone formation was significantly reduced in OVX rats, but restored in DES-treated rats. Treatment with either RDD or PHD enhanced trabecular bone formation remarkably. No significant change in bone formation was observed in CSD-treated rats. OPG expression of protein and mRNA was reduced significantly in OB and bMSC of OVX control rats. RANKL expression of protein and mRNA was increased significantly in OB and bMSC of OVX control rats. These effects were substantially reversed by treatment with DES, RDD, or PHD in OB and bMSC of OVX rats. No significant changes in either OPG or RANKL expression were observed in OB and bMSC of OVX rats treated with CSD.*
RDD and PHD were hence found to increase bone formation by stim- ulating overexpression of OPG and downregulation of RANKL in OB and bMSC. This suggests that RDD and PHD may be used as alternative therapeutic agents for postmenopausal osteoporosis.7 *
Radix Dipsaci
The effects of Radix Dipsaci extract (RDE) on postmenopausal osteo- porosis have been evaluated. 16 weeks treatment of RDE slowed weight gain and prevented the loss of bone mass induced by ovariectomy. The prevention effect on bone loss was due to the alteration of the rate of bone remodeling, which could be inferred from the decreased level of bone turnover markers, such as serum ALP, OC and urinary DPD. The changes in urinary calcium and phosphorus excretion levels provided the same evidence. The treatment could also enhance the bone strength and prevent the deterioration of trabecular microarchitecture. Radix Dipsaci extract hence has the potential to be used in the treatment of postmenopausal osteoporosis.8 *
Psoralea corylifolia
The ethanol extract of Psoralea corylifolia L. (PCE) and its active compo- nent have been investigated for their protection against bone loss in ovariectomised rats. Seventy female Sprague-Dawley rats were assigned to either a non-operated group (n = 10) or an ovariectomised group (n = 60). The ovariectomised group was subdivided into six groups of ten: vehicle group, two bakuchiol-treated groups (dose of 15 mg/kg per d or 30 mg/kg per d), two PCE-supplemented groups (0.25 % or 0.5 % extracts of diets) and a 17beta-oestradiol (E2)-treated group (20 microg/kg per d). Baku- chiol has a three-fold higher binding affinity for ERalpha than for ERbeta. Bakuchiol and PCE treatments had no uterotrophic activity even though they demonstrated oestrogenic activity in the in vitro assays. Bakuchiol and PCE treatments reduced postmenopausal bone loss by increasing alkaline phosphatase, Ca2+ concentrations, serum E2 concentration and bone mineral density, and by decreasing the inorganic P level. Bakuchiol and PCE treatments may hence protect against bone loss.9 *
References
Zhao, Y-j., Hu, J., Chen, J. A systematic evaluation on Xianlinggubao capsule for postmenopausal osteopo- rosis. Tian Jin Zhong Yi Yao. 2010; 27(4): 279-282.
Tian, F-m., Zhang, L., Luo, Y., Song, Y-q., Jiao, A., Cheng, T. Xianlinggubao promotes vascular formation in osteoporotic fracture callus. Zhong Guo Zu Zhi Gong Cheng Yan Jiu Yu Lin Chuang Kang Fu. 2011; 15(28): 5161-5164.
Wang, J., Hu, X., Zhuo, J., Li, Y., Wang, L. Effect of Xianlinggubao on bone density and metabolism of ovariectomized rats. Shaan Xi Zhong Yi Xue Yuan Yuan Bao. 2010; (3): 64-65.
Zhang, Y., Yang, G., Sun, G-z. The experiment study of the effect of Xianlinggubao medicated serum on the co-culture system of mouse osteoblast and osteoclast. Tianjin. Zhong Guo Lao Nian Xue Za Zhi. 2011; 31(14): 2670-2673.
Xing, L., Jiao, Y-h., Geng, L-h., Sun, Y.. Xianlinggubao for treatment of osteoporotic rats: Serological and bone histomorphometric evaluation. Zhong Guo Zu Zhi Gong Cheng Yan Jiu Yu Lin Chuang Kang Fu. 2011; 15(15): 2786-2789.
Liu, M., Zhong, C., He, RX., Chen, LF. Icariin associated with exercise therapy is an effective treatment for postmenopausal osteoporosis. Chin Med J (Engl). 2012 May;125(10):1784-9.
Liu, M., Xiao, GG., Rong, P., et al. Therapeutic effects of Radix Dipsaci, Pyrola Herb, and Cynomorium Son- garicum on bone metabolism of ovariectomized rats. BMC Complement Altern Med. 2012 May 28;12(1):67.
Liu, ZG., Zhang, R., Li, C., et al. The osteoprotective effect of Radix Dipsaci extract in ovariectomized rats. J Ethnopharmacol. 2009 May 4;123(1):74-81. Epub 2009 Mar 4.
Lim, S.H., Ha T.Y., Kim S.R., Ahn J., Park H.J., Kim S. Ethanol extract of Psoralea corylifolia L. and its main constituent, bakuchiol, reduce bone loss in ovariectomised Sprague-Dawley rats. Br J Nutr. 2009 Apr;101(7):1031-9. Epub 2008 Sep 19.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Supplement FactsServing Size:1 capsules Servings Per Container: 60 |
||
|---|---|---|
|
Amount Per Serving |
% Daily Value |
|
| Epimedium (leaf) (Yin Yang Huo) | 30mg | † |
| Epimedium (contains icariin extract) (above ground parts) | 100mg | † |
| Japanese teasel (root) (Xu Duan) | 80mg | † |
| Psoralea (fruit) (Bu Gu Zhi) | 30mg | † |
| Psoralea (contains Bakuchiol) (Bu Gu Zhi) | 2mg | † |
| Rehmannia (root) Di Huang | 50mg | † |
| Salvia (root) (Dan Shen) | 60mg | † |
| Anemarrhena (rhizome) (Zhi Mu) | 50mg | † |
| Pyrola Calliantha H Andres (herb) (Lu Xian Cao) | 88mg | † |
Other Ingredients: Vegetable cellulose (hypromellose); Vegetable Stearic Acid; Microcrystalline Cellulose and Vegetable Magnesium Stearate.
Does Not Contain Wheat, gluten, soy, milk, eggs, fish, crustacean shellfish, tree nuts, peanuts
Ostpo
60 x 500 mg Vegetarian Capsules
Product Overview
Ostpo is a formulation of herbs that contain isolates traditionally shown and by modern research to support optimum bone health. Bakuchiol from Psoralea is one such substance. Icariin a flavonol glycoside found in many medicinal plants has also been linked to having a therapeutic role in supporting bone health and supporting optimum bone density. *
Actions
•Supports optimum bone health*
•Supports maintenance of optimum bone density*
Suggested Use:
2-4 capsules daily
Warning:
Do not use if taking Aricept, Reminyl or Exelon, Warfarin, or when pregnant, or nursing.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Patients administered the OSTPO Capsule in clinical trials showed improved bone marrow density and serum oestradiol compared with those administered calcium. However, because of the small sample size of these trials, the conclusions need to be interpreted cautiously, and more well-designed, high-quality random-controlled trials are required.1 Controversy still exists regarding the healing effect and associated mechanism underlying OSTPO capsules in osteoporotic early process fracture healing and ovariectomized patients. In a study involving fifty female 12-week old Sprague-Dawley rats, OSTPO treatment enhanced the bone mineral density, X-ray radiography score and quantity of callus tissues in rats in the ovariectomy and fracture groups. No significant difference was observed in bone morphogenetic protein-2 expression. OSTPO also promoted the early vascular formation of osteoporotic fracture healing in ovariectomized rats.2 *
In a controlled study in 40 female SD rats, OSTPO was found to increase bone density and E2 levels of ovariectomised rats, and is effective in the treatment of osteoporosis.3 *
OSTPO-medicated serum promoted osteoblast mineralization in a mouse osteoblast MC3T3-E1 and an osteoclast induced by a mouse single nucleus macrophage RAW 264 co-culture system. Additionally, it reduced the count of absorption lacuna on bone chips. OSTPO-medicated serum could increase the ratio of OPG/RANKL in a dose dependent manner.4 *
The treatment for osteoporosis is presently targeted on the inhibition of bone-resorption, and OSTPO has been reported to be effective for pro- moting bone formation. In a randomised study involving 24 rats suffering osteoporosis induced by ovariectomy, OSTPO was found to partly prevent bone loss by inhibiting bone resorption and promoting bone formation, thereby reducing the bone turnover level.5 *
Icariin
The effects of icariin treatment combined with exercise therapy on bone parameters and body weight of ovariectomized rats were investigated. Exercise combined with icariin was found to have a synergistic effect in the early prevention of osteoporosis in ovariectomized rats. The effects of icariin and exercise on osteoporosis require further exploration.6 *
Pyrola calloantha and Radix Dipsaci
The effects of herbal medicines, such as Radix Dipsaci (RDD), Pyrola Herb (PHD), and Cynomorium songaricum decoction (CSD), on osteoporotic rats induced by ovariectomy (OVX) have been investigated. Compared to the normal control and non-overiectomized rats, trabecular bone formation was significantly reduced in OVX rats, but restored in DES-treated rats. Treatment with either RDD or PHD enhanced trabecular bone formation remarkably. No significant change in bone formation was observed in CSD-treated rats. OPG expression of protein and mRNA was reduced significantly in OB and bMSC of OVX control rats. RANKL expression of protein and mRNA was increased significantly in OB and bMSC of OVX control rats. These effects were substantially reversed by treatment with DES, RDD, or PHD in OB and bMSC of OVX rats. No significant changes in either OPG or RANKL expression were observed in OB and bMSC of OVX rats treated with CSD.*
RDD and PHD were hence found to increase bone formation by stim- ulating overexpression of OPG and downregulation of RANKL in OB and bMSC. This suggests that RDD and PHD may be used as alternative therapeutic agents for postmenopausal osteoporosis.7 *
Radix Dipsaci
The effects of Radix Dipsaci extract (RDE) on postmenopausal osteo- porosis have been evaluated. 16 weeks treatment of RDE slowed weight gain and prevented the loss of bone mass induced by ovariectomy. The prevention effect on bone loss was due to the alteration of the rate of bone remodeling, which could be inferred from the decreased level of bone turnover markers, such as serum ALP, OC and urinary DPD. The changes in urinary calcium and phosphorus excretion levels provided the same evidence. The treatment could also enhance the bone strength and prevent the deterioration of trabecular microarchitecture. Radix Dipsaci extract hence has the potential to be used in the treatment of postmenopausal osteoporosis.8 *
Psoralea corylifolia
The ethanol extract of Psoralea corylifolia L. (PCE) and its active compo- nent have been investigated for their protection against bone loss in ovariectomised rats. Seventy female Sprague-Dawley rats were assigned to either a non-operated group (n = 10) or an ovariectomised group (n = 60). The ovariectomised group was subdivided into six groups of ten: vehicle group, two bakuchiol-treated groups (dose of 15 mg/kg per d or 30 mg/kg per d), two PCE-supplemented groups (0.25 % or 0.5 % extracts of diets) and a 17beta-oestradiol (E2)-treated group (20 microg/kg per d). Baku- chiol has a three-fold higher binding affinity for ERalpha than for ERbeta. Bakuchiol and PCE treatments had no uterotrophic activity even though they demonstrated oestrogenic activity in the in vitro assays. Bakuchiol and PCE treatments reduced postmenopausal bone loss by increasing alkaline phosphatase, Ca2+ concentrations, serum E2 concentration and bone mineral density, and by decreasing the inorganic P level. Bakuchiol and PCE treatments may hence protect against bone loss.9 *
References
Zhao, Y-j., Hu, J., Chen, J. A systematic evaluation on Xianlinggubao capsule for postmenopausal osteopo- rosis. Tian Jin Zhong Yi Yao. 2010; 27(4): 279-282.
Tian, F-m., Zhang, L., Luo, Y., Song, Y-q., Jiao, A., Cheng, T. Xianlinggubao promotes vascular formation in osteoporotic fracture callus. Zhong Guo Zu Zhi Gong Cheng Yan Jiu Yu Lin Chuang Kang Fu. 2011; 15(28): 5161-5164.
Wang, J., Hu, X., Zhuo, J., Li, Y., Wang, L. Effect of Xianlinggubao on bone density and metabolism of ovariectomized rats. Shaan Xi Zhong Yi Xue Yuan Yuan Bao. 2010; (3): 64-65.
Zhang, Y., Yang, G., Sun, G-z. The experiment study of the effect of Xianlinggubao medicated serum on the co-culture system of mouse osteoblast and osteoclast. Tianjin. Zhong Guo Lao Nian Xue Za Zhi. 2011; 31(14): 2670-2673.
Xing, L., Jiao, Y-h., Geng, L-h., Sun, Y.. Xianlinggubao for treatment of osteoporotic rats: Serological and bone histomorphometric evaluation. Zhong Guo Zu Zhi Gong Cheng Yan Jiu Yu Lin Chuang Kang Fu. 2011; 15(15): 2786-2789.
Liu, M., Zhong, C., He, RX., Chen, LF. Icariin associated with exercise therapy is an effective treatment for postmenopausal osteoporosis. Chin Med J (Engl). 2012 May;125(10):1784-9.
Liu, M., Xiao, GG., Rong, P., et al. Therapeutic effects of Radix Dipsaci, Pyrola Herb, and Cynomorium Son- garicum on bone metabolism of ovariectomized rats. BMC Complement Altern Med. 2012 May 28;12(1):67.
Liu, ZG., Zhang, R., Li, C., et al. The osteoprotective effect of Radix Dipsaci extract in ovariectomized rats. J Ethnopharmacol. 2009 May 4;123(1):74-81. Epub 2009 Mar 4.
Lim, S.H., Ha T.Y., Kim S.R., Ahn J., Park H.J., Kim S. Ethanol extract of Psoralea corylifolia L. and its main constituent, bakuchiol, reduce bone loss in ovariectomised Sprague-Dawley rats. Br J Nutr. 2009 Apr;101(7):1031-9. Epub 2008 Sep 19.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.